Clinical impact of serum soluble SLAMF7 in multiple myeloma

The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishibashi, Mariko, Soeda, Saori, Sasaki, Makoto, Handa, Hiroshi, Imai, Yoichi, Tanaka, Norina, Tanosaki, Sakae, Ito, Shigeki, Odajima, Takeshi, Sugimori, Hiroki, Asayama, Toshio, Sunakawa, Mika, Kaito, Yuta, Kinoshita, Ryosuke, Kuribayashi, Yasuko, Onodera, Asaka, Moriya, Keiichi, Tanaka, Junji, Tsukune, Yutaka, Komatsu, Norio, Inokuchi, Koiti, Tamura, Hideto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205184/
https://www.ncbi.nlm.nih.gov/pubmed/30410677
http://dx.doi.org/10.18632/oncotarget.26196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205184/
https://www.ncbi.nlm.nih.gov/pubmed/30410677
http://dx.doi.org/10.18632/oncotarget.26196

Ejemplares similares